# Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

> **NCT04530487** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Desmoplastic Small Round Cell Tumor
- Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Desmoplastic Small Round Cell Tumor
- Recurrent Malignant Peripheral Nerve Sheath Tumor
- Recurrent Malignant Solid Neoplasm
- Recurrent Neuroblastoma
- Recurrent Rhabdomyosarcoma
- Refractory Desmoplastic Small Round Cell Tumor
- Refractory Malignant Peripheral Nerve Sheath Tumor
- Refractory Malignant Solid Neoplasm
- Refractory Neuroblastoma
- Refractory Rhabdomyosarcoma

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclosporine
- **DRUG:** Etoposide
- **DRUG:** Fludarabine Phosphate
- **BIOLOGICAL:** Lapine T-Lymphocyte Immune Globulin
- **DRUG:** Melphalan
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus
- **DRUG:** Thiotepa

## Key facts

- **NCT ID:** NCT04530487
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-19
- **Primary completion:** 2024-08-26
- **Final completion:** 2024-08-26
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** PI Request
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04530487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04530487, "Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04530487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*